131047TRPA1 hit expansion and validationClosedFeasibility StudiesInnovate UKRespiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are increasing within the global population. The UK has the highest prevalence of asthma in the world, with ~9 million people of all ages and race affected and where 90% of deaths are preventable. 3.2 Million people have COPD and ~23,000 people die from the disease each year, making COPD the UK’s fifth biggest killer disease. This increasing problem is recognised by the introduction of government guidelines recently set up to improve diagnosis and hence initiate earlier treatment of both diseases. However, current drugs are only able to treat the symptoms. As the diseases progress and symptoms get more aggressive, these drugs simply do not provide adequate relief. It is our intention to find a new drug that is superior to the current treatments. Only when such a drug is available can we begin to see an increase in the quality of life to the people affected by these chronic diseases.